Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma

Bellmunt, Joaquim; Ribas, Antoni; Eres, N; Albanell, Joan; Almanza, C.; Bermejo, Begoña; Solé, Luis-Alfonso; Baselga, José

doi:10.1002/(sici)1097-0142(19971115)80:10<1966::aid-cncr14>3.0.co;2-w

Cited by 221 publications

(77 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, the median and 3-year survival were 42 months (95% confidence interval [CI), 33-51) and 54% (95% CI, 48-61), respectively. Considering only those patients with high-risk features, the median and 3-year survival were 16 months (95% CI, [12][13][14][15][16][17][18][19][20] and 19% (95% CI, 5-33), respectively. For patients with or without preoperative CKD, the median survival and 3-year survival were 37 months (95% CI, 29-44) and 51% (95% CI, 42-59) and 64 months (95% CI, 34-104) and 58% (95% CI, 49-68), respectively (P ¼ .007).…”

Section: Resultsmentioning

confidence: 99%

“…However, carboplatin-based and other noncisplatin based regimens are widely considered to be inferior to MVAC and gemcitabine-cisplatin. 12,[19][20][21] For example, in a randomized trial of MVAC versus methotrexate-vinblastine-carboplatin in patients with metastatic UC, a significantly reduced cancer-specific survival was seen in patients receiving methotrexate-vinblastine-carboplatin (median 9 vs 16 months, P ¼ .03). 19 A single-study arm phase 2 trial of neoadjuvant paclitaxel-gemcitabine-carboplatin for muscleinvasive UC of the bladder also reported fewer pathologic complete responses than had been reported in other trials of neoadjuvant CBCC in similar patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy

Lane

Smith

Larson

et al. 2010

Cancer

189

117

View full text Add to dashboard Cite

BACKGROUND:The prevalence of chronic kidney disease (CKD) in patients with upper tract urothelial carcinoma (UTUC) is poorly defined, both before and after nephrouretectomy. Although multimodal treatment paradigms for UTUC are under‐developed, this has important implications on patients' ability to receive cisplatin‐based combination chemotherapy (CBCC).METHODS:Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease formula in 336 patients with UTUC, who were treated at the Cleveland Clinic by nephroureterectomy since 1992. An eGFR cutoff of 60 mL/min/1.73 m2 was used to determine the presence of CKD and eligibility for CBCC.RESULTS:Median age was 72 years and median preoperative eGFR was 59 mL/min/1.73m2. Before nephroureterectomy, only 48% of patients were eligible to receive CBCC and this decreased to 22% postoperatively (P < .001). In the 144 patients with pT2‐pT4 and/or pN1‐pN3 disease who are suitable to receive CBCC, these proportions were 40% and 24%, respectively (P = .009). Although 50 patients overall received some form of perioperative chemotherapy, only 3 and 11 patients received neoadjuvant and adjuvant CBCC, respectively.CONCLUSIONS:CKD is prevalent in the UTUC population and a minority of patients has an optimal eGFR to receive neoadjuvant CBCC. Nephrouretectomy may eliminate CBCC as a therapeutic option in 49% of high‐risk patients if it is deferred to the adjuvant setting. Multimodal treatment strategies for UTUC should focus on neoadjuvant chemotherapy, as few patients are eligible for adjuvant CBCC because of the substantial decline in eGFR caused by nephroureterectomy. Cancer 2010. © 2010 American Cancer Society.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy

Lane

Smith

Larson

et al. 2010

Cancer

189

117

View full text Add to dashboard Cite

show abstract

“…Phase II trials of carboplatin, as a substitution for cisplatin in first-line chemotherapy regimens, demonstrated that carboplatin-based therapy was less effective than cisplatin-based therapy. However, there is few data on carboplatin as a substitution for cisplatinbased therapy in second-line chemotherapy (Petrioli et al, 1996;Bellmunt et al, 1997). Randomised trials with carboplatin-based regimens in patients who failed first-line platinum-based chemotherapy and development of new combinations consisting of safer and more effective agents is needed for the treatment of patients with depleted marrow reserves and impaired renal function after the failure of first-line chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy

et al. 2007

View full text Add to dashboard Cite

We investigated the safety and efficacy of a methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) combination regimen as second-line chemotherapy for patients with advanced or metastatic transitional cell carcinoma who failed first-line gemcitabine and cisplatin (GC) chemotherapy. Thirty patients who had progressed or relapsed after GC chemotherapy as first-line treatment were enrolled in this study. The major toxicities were neutropaenia and thrombocytopaenia. A grade 3 or 4 neutropaenia occurred in 19 (63.3%) and a grade 3 or 4 thrombocytopaenia developed in nine patients (30.0%). There were no life-threatening complications during the study. The overall response was 30%. A complete response was achieved in two patients (6.7%) and a partial response in seven (23.3%). The overall disease control rate was 50%. Seven out of 16 patients who had responded previously to GC responded to M-VAC, while 2 out of 14 who had not responded to GC responded to M-VAC. The median response duration was 3.9 months and the median progression-free survival was 5.3 months. The median overall survival was 10.9 months. M-VAC showed encouraging efficacy and reversible toxicities in patients who had progressed after GC chemotherapy and, especially, M-VAC appears to be a reasonable option as a sequential treatment regimen in patients who responded previously to GC chemotherapy.

show abstract

“…Carboplatin exhibits less nephrotoxicity and no ototoxicity and is often used as an alternative for cisplatin (7). Cisplatin has demonstrated superior activity over carboplatin in several studies of patients with squamous cell carcinoma of the head and neck (SCCHN) and bladder cancer (8)(9)(10)(11)(12). A meta-analysis of randomized trials comparing cisplatin versus carboplatin-based therapy in patients with bladder cancer demonstrated that cisplatin-based therapy significantly improved complete response and overall response compared with carboplatin (13).…”

Section: Introductionmentioning

confidence: 99%

Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors

Subbiah

Grilley‐Olson

Combest

et al. 2018

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: NC-6004, a novel cisplatin nanoparticle developed using micellar technology exhibits sustained release of cisplatin and selective distribution to tumors. Preclinical data demonstrated a favorable tolerability profile and preserved or improved antitumor activity compared with cisplatin across animal models. We evaluated the safety and tolerability of NC-6004 and gemcitabine using a Bayesian continual reassessment model (N-CRM) to determine the optimal dose.Experimental Design: Patients with advanced solid tumors received NC-6004 at 60 to 180 mg/m 2 on day 1 and gemcitabine at 1,250 mg/m 2 on days 1 and 8 every 3 weeks. Dose escalation of NC-6004 began with a single patient run-in until a dose-limiting toxicity occurred at 180 mg/m 2 . Cohorts of four patients were enrolled at doses predicted by the N-CRM. The maximum tolerated dose (MTD) was defined as having the greatest probability of target toxicity <25%. Quality of life was assessed using EORTC-QLQ-C30.Results: Among 22 patients, the most common grade III/IV hematologic adverse events were leukopenia (68%) and thrombocytopenia (59%). Of 20 pretreated patients evaluable for response, half were previously exposed to a platinum agent. The MTD was 135 mg/m 2 . Nine patients were treated at the MTD with median treatment duration of 15 weeks (range, 3-50). Tumor shrinkage occurred in 11 (55%), partial responses in 3 (15%), and stable disease in 14 (70%). Most patients reported stable or improved EORTC QLQ-C30 scores.Conclusions: Greater cisplatin equivalent doses were achieved with no clinically significant neuro-, oto-, or nephrotoxicity. These data demonstrate tolerability and promising activity of NC-6004 in combination with gemcitabine.

show abstract

Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma

Cited by 221 publications

References 28 publications

Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy

Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy

Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy

Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors

Contact Info

Product

Resources

About